Skip to main content
PACS
NYSE Industrial Applications And Services

PACS Raises 2026 EBITDA Guidance to $685M-$695M on 33.6% Q3 EBITDA Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$46.68
Mkt Cap
$7.391B
52W Low
$10.31
52W High
$50.38
52W Position info
353% above low
Off High info
7.3% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PACS has more than doubled off its 52-week low of $10.31.

Summary

PACS posted Q3 revenue of $1.50 billion (+11.5%) and Adjusted EBITDA of $175.7 million (+33.6%), then raised 2026 Adjusted EBITDA guidance to $685M-$695M and closed its Florida and Texas acquisitions.


Key Events · Earnings and Guidance · PACS

  • Q3 Revenue Up 11.5% to $1.50B

    Revenue was $1.50 billion versus $1.34 billion a year ago; net income rose 16.2% to $60.8 million and diluted EPS was $0.37.

  • Adjusted EBITDA Jumps 33.6%

    Adjusted EBITDA reached $175.7 million, up $44.2 million from $131.5 million, with Adjusted EPS of $0.63 (+37.0%).

  • 2026 EBITDA Guidance Raised

    Full-year 2026 Adjusted EBITDA guidance lifted to $685M-$695M from $640M-$660M, and revenue guidance to $5.95B-$6.05B from $5.75B-$5.85B.

  • Florida and Texas Deals Closed

    All 32 Florida facilities closed October 1, 2026, and all 11 Texas facilities closed as of November 1, 2026; portfolio now spans 398 operations in 21 states.


Analysis · PACS · Industrial Applications And Services

PACS beat its own trajectory: Q3 revenue rose 11.5% to $1.50 billion while Adjusted EBITDA jumped 33.6% to $175.7 million, and management lifted full-year 2026 Adjusted EBITDA guidance to $685M-$695M from $640M-$660M (about 37% growth at the midpoint). Revenue guidance moved up to $5.95B-$6.05B. The company also closed both pending deals — all 32 Florida facilities on October 1 and 11 Texas facilities by November 1 — so the growth pipeline is now in the numbers rather than a promise. With net leverage at 0.2x and $707.4 million of liquidity, the balance sheet supports more acquisitions. The offset: stock-based compensation nearly quadrupled to $45.3 million this quarter, and the previously disclosed DOJ/SEC investigations and material weaknesses remain unresolved overhangs.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PACS was trading at $46.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $10.31 to $50.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PACS - Latest Insights

PACS
Nov 03, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.68
Real-time Price: $46.57 info
Change: -$0.110 (-0.24%) info
Market Cap: $7.349B info
PACS
Nov 03, 2026, 4:15 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $46.68
Real-time Price: $46.57 info
Change: -$0.110 (-0.24%) info
Market Cap: $7.349B info
PACS
Sep 21, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.06
Real-time Price: $46.57 info
Change: +$4.51 (+11%) info
Market Cap: $7.349B info
PACS
Sep 01, 2026, 4:16 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $42.14
Real-time Price: $46.57 info
Change: +$4.43 (+11%) info
Market Cap: $7.349B info
PACS
Aug 04, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $45.15
Real-time Price: $46.57 info
Change: +$1.42 (+3%) info
Market Cap: $7.349B info